OP Asset Management Ltd Invests $11.69 Million in Vertex Pharmaceuticals Incorporated $VRTX

Key Points

• OP Asset Management opened a new position in Vertex Pharmaceuticals in the first quarter, buying 26,189 shares worth about $11.69 million.
• Vertex continues to receive bullish analyst support, with several firms raising targets or upgrading the stock; the consensus rating remains Moderate Buy with an average price target of $555.91.
• Recent company updates were positive, including encouraging data for CASGEVY in children and renewed optimism around povetacicept as a potential growth driver beyond Vertex’s cystic fibrosis franchise.

OP Asset Management Ltd acquired a new position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 26,189 shares of the pharmaceutical company's stock, valued at approximately $11,694,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in VRTX. Motiv8 Investments LLC bought a new stake in shares of Vertex Pharmaceuticals in the 4th quarter worth approximately $26,000. Colonial Trust Co SC grew its holdings in Vertex Pharmaceuticals by 118.8% during the third quarter. Colonial Trust Co SC now owns 70 shares of the pharmaceutical company's stock valued at $27,000 after purchasing an additional 38 shares during the period. Swiss RE Ltd. bought a new position in Vertex Pharmaceuticals during the fourth quarter valued at $28,000. Eagle Bay Advisors LLC purchased a new stake in Vertex Pharmaceuticals in the fourth quarter worth $29,000. Finally, IMG Wealth Management Inc. increased its position in Vertex Pharmaceuticals by 277.8% in the fourth quarter. IMG Wealth Management Inc. now owns 68 shares of the pharmaceutical company's stock worth $31,000 after buying an additional 50 shares during the last quarter. 90.96% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. HC Wainwright increased their price target on Vertex Pharmaceuticals from $591.00 to $641.00 and gave the stock a "buy" rating in a research note on Tuesday, March 10th. Sanford C. Bernstein reduced their target price on shares of Vertex Pharmaceuticals from $577.00 to $572.00 and set an "outperform" rating for the company in a research note on Tuesday, May 5th. Weiss Ratings raised shares of Vertex Pharmaceuticals from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Monday, May 18th. Wall Street Zen upgraded shares of Vertex Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Saturday, June 20th. Finally, Jefferies Financial Group assumed coverage on shares of Vertex Pharmaceuticals in a research note on Tuesday, March 10th. They issued a "buy" rating and a $580.00 price objective for the company. Twenty-two investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $555.91.

Vertex Pharmaceuticals News Summary

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Vertex received an upgrade-driven boost from commentary highlighting povetacicept as a potential new growth driver, reinforcing optimism that the company’s pipeline can support earnings beyond its cystic fibrosis franchise. Article Title
• Positive Sentiment: New pediatric data for CASGEVY showed strong clinical benefits and a consistent safety profile in children, supporting Vertex’s regulatory and commercial outlook for its CRISPR-based therapy. Article Title
• Positive Sentiment: Analyst sentiment remains constructive, with multiple firms reiterating bullish views and price targets above the current share price, suggesting continued institutional confidence in Vertex’s longer-term growth story. Article Title

Vertex Pharmaceuticals Stock Up 1.4%

NASDAQ:VRTX opened at $475.20 on Thursday. The business's 50-day moving average price is $440.46 and its two-hundred day moving average price is $453.72. Vertex Pharmaceuticals Incorporated has a twelve month low of $362.50 and a twelve month high of $507.92. The stock has a market cap of $120.61 billion, a P/E ratio of 28.19, a PEG ratio of 2.00 and a beta of 0.30.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last issued its quarterly earnings data on Monday, May 4th. The pharmaceutical company reported $4.47 EPS for the quarter, topping the consensus estimate of $4.24 by $0.23. The company had revenue of $2.99 billion during the quarter, compared to analyst estimates of $2.99 billion. Vertex Pharmaceuticals had a return on equity of 23.86% and a net margin of 35.51%.Vertex Pharmaceuticals's revenue was up 8.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $4.06 earnings per share. On average, equities research analysts expect that Vertex Pharmaceuticals Incorporated will post 17.02 EPS for the current fiscal year.

Insider Buying and Selling at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, CMO Carmen Bozic sold 1,020 shares of the business's stock in a transaction that occurred on Thursday, June 18th. The shares were sold at an average price of $462.17, for a total value of $471,413.40. Following the completion of the transaction, the chief marketing officer owned 15,933 shares of the company's stock, valued at $7,363,754.61. The trade was a 6.02% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Sangeeta N. Bhatia sold 318 shares of the stock in a transaction on Monday, May 4th. The stock was sold at an average price of $423.73, for a total transaction of $134,746.14. Following the completion of the transaction, the director directly owned 4,924 shares in the company, valued at $2,086,446.52. The trade was a 6.07% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 16,215 shares of company stock worth $7,272,420 over the last three months. 0.20% of the stock is owned by insiders.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex's marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.